Pelegrin Mireia, Naranjo-Gomez Mar, Piechaczyk Marc
Equipe Labellisée par la Ligue contre le Cancer - Institut de Génétique Moléculaire de Montpellier, UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, Université de Montpellier, 163 rue Auguste Broussonnet, 34090 Montpellier, France.
Equipe Labellisée par la Ligue contre le Cancer - Institut de Génétique Moléculaire de Montpellier, UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, Université de Montpellier, 163 rue Auguste Broussonnet, 34090 Montpellier, France.
Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005.
Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.
单克隆抗体（mAbs）越来越被视为对抗严重病毒性疾病的药物。到目前为止，它们基本上是根据其病毒中和活性和/或细胞杀伤活性来选择和使用的，通过直接机制来抑制病毒传播。然而，越来越多的证据表明，它们还可以在免疫治疗期间通过调动受感染个体的内源性免疫系统来诱导持久的保护性抗病毒免疫。利用这一特性可能会彻底改变基于抗病毒单克隆抗体的免疫疗法，对患者和医疗系统都有益处。
